A RANDOMIZED PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, BEVACIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, BEVACIZUMAB IN THE TREATMENT OF pMMR, TP53 MUTATED ADVANCED OR RECURRENT ENDOMETRIAL CANCER

17105NRG-GY035-NCT07198074OpenA RANDOMIZED PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, BEVACIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, BEVACIZUMAB IN THE TREATMENT OF pMMR, TP53 MUTATED ADVANCED OR RECURRENT ENDOMETRIAL CANCERNRG-GY035NCT07198074NationalAdultTreatmentIIINationalCorpus UteriHoskins, EbonyMedstar Washington Hospital Center : Reva PersaudGyn. Onc.Oncology GroupMHRI Washington Cancer Institute17525Reva PersaudReva PersaudReva.S.Persaud@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>